Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic J Kaye

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerJulia K Rotow, Philippe Gui, Wei Wu, et al.
Nature Medicine|August 13, 2021
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trialBenjamin C Creelan, Chao Wang, Jamie K Teer, et al.
Biomaterials|December 24, 2025
Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerabilityMiao Huang, Yinong Chen, Chenyu Liang, et al.
Nature|February 19, 2010
The landscape of somatic copy-number alteration across human cancersRameen Beroukhim, Craig H Mermel, Dale Porter, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerJulia K Rotow, Philippe Gui, Wei Wu, et al.
Nature Medicine|August 13, 2021
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trialBenjamin C Creelan, Chao Wang, Jamie K Teer, et al.
Biomaterials|December 24, 2025
Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerabilityMiao Huang, Yinong Chen, Chenyu Liang, et al.
Nature|February 19, 2010
The landscape of somatic copy-number alteration across human cancersRameen Beroukhim, Craig H Mermel, Dale Porter, et al.
Pageof 8